ArticleScientific reports2025
Efficacy of the novel MIGS implant Wistend compared to Kahook Dual Blade in the treatment of experimental ocular hypertension in rabbits.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
To evaluate and compare the efficacy of novel microinvasive glaucoma surgery (MIGS) device implants Wistend and Kahook Dual Blade (KDB) in an experimental ocular hypertension model. Twelve New Zealand white rabbits were randomized into four groups (blank, sham-operated, Wistend and KDB groups) after establishment of an ocular hypertension animal model. Intraocular pressure (IOP) was observed over three months. Eaton and Draize scores, Swept-source optical coherence tomography (SS-OCT), fundus photography were used to evaluate ocular health and confirm microstent placement. Both the Wistend and the KDB significantly lowered IOP over the three-month follow-up. At 7,10,20, and 30 days post-operation, there were significant differences in IOP reduction between the Wistend and the KDB groups (P < 0.05). Postoperative assessments showed that the anterior and posterior segments of the eyes remained healthy, with no notable adverse events. Wistend and KDB both effectively reduced IOP in experimental ocular hypertension, and a stable and significant IOP reduction was maintained throughout the 3-month postoperative follow-up period. The findings may provide potentially experimental rationale for the selection of the MIGS devices Wistend and KDB for glaucoma patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.